• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用基因敲除小鼠模型研究 FcγR 对 8C2(一种鼠源 IgG1 单克隆抗体)组织分布和消除的影响。

Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.

出版信息

Int J Pharm. 2012 Dec 15;439(1-2):8-16. doi: 10.1016/j.ijpharm.2012.09.042. Epub 2012 Sep 24.

DOI:10.1016/j.ijpharm.2012.09.042
PMID:23018115
Abstract

The current work examines the role of Fcγ-receptors on the elimination and tissue distribution of 8C2, a model murine IgG1 monoclonal antibody. The plasma pharmacokinetics of (125)Iodine-labeled 8C2 were investigated in C57BL/6 control mice, FcγRI/RIII knockout mice, and FcγRIIb knockout mice, following intravenous doses of 0.04, 0.1 and 0.4 mg/kg. Plasma samples were collected and radioactivity was counted. Concentration data were analyzed with a population pharmacokinetic model. Additionally, the tissue disposition of 8C2 was investigated using whole body autoradioluminography (WBAL) and via counting excised tissues. Areas under the plasma concentration vs. time curves AUC(0-10 days) ±SD (nM×days) were: 12.3±0.3, 12.5±1.3 and 15.1±1.2 at 0.04 mg/kg; 39.3±2.0, 28.9±2.7 and 42.0±9.4 at 0.1 mg/kg; and 225±19, 158±19 and 204±26 at 0.4 mg/kg in C57BL/6, FcγRI/RIII(-/-) and FcγRIIb(-/-) mice. Strain was not a statistically significant predictor for any of the parameters of the population model. 8C2 plasma clearance, distribution clearance, and central compartment volume were 0.00543 L/days/kg, 0.0598 L/days/kg, and 0.057 L/kg. No substantial differences in 8C2 tissue uptake were identified by analysis of excised tissues or by WBAL. In conclusion, FcγR knockout is associated with only minor effects on the plasma and tissue disposition of 8C2, a model murine IgG1 mAb.

摘要

目前的工作研究了 Fcγ-受体在 8C2(一种模型鼠 IgG1 单克隆抗体)的清除和组织分布中的作用。在静脉注射 0.04、0.1 和 0.4mg/kg 的 125I 标记的 8C2 后,在 C57BL/6 对照小鼠、FcγRI/RIII 基因敲除小鼠和 FcγRIIb 基因敲除小鼠中研究了(125)碘标记的 8C2 的血浆药代动力学。收集血浆样本并计数放射性。使用群体药代动力学模型分析浓度数据。此外,通过全身放射自显影(WBAL)和计数切除组织研究了 8C2 的组织分布。血浆浓度-时间曲线下面积 AUC(0-10 天)±SD(nM×天)为:0.04mg/kg 时为 12.3±0.3、12.5±1.3 和 15.1±1.2;0.1mg/kg 时为 39.3±2.0、28.9±2.7 和 42.0±9.4;0.4mg/kg 时为 225±19、158±19 和 204±26,在 C57BL/6、FcγRI/RIII(-/-)和 FcγRIIb(-/-)小鼠中。品系不是群体模型中任何参数的统计学上显著预测因子。8C2 血浆清除率、分布清除率和中央室容积分别为 0.00543 L/days/kg、0.0598 L/days/kg 和 0.057 L/kg。通过对切除组织或 WBAL 的分析,未发现 8C2 组织摄取有实质性差异。总之,FcγR 敲除仅对 8C2 的血浆和组织分布产生微小影响,8C2 是一种模型鼠 IgG1 mAb。

相似文献

1
Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody.应用基因敲除小鼠模型研究 FcγR 对 8C2(一种鼠源 IgG1 单克隆抗体)组织分布和消除的影响。
Int J Pharm. 2012 Dec 15;439(1-2):8-16. doi: 10.1016/j.ijpharm.2012.09.042. Epub 2012 Sep 24.
2
Investigation of the role of FcγR and FcRn in mAb distribution to the brain.研究 FcγR 和 FcRn 在单抗向脑内分布中的作用。
Mol Pharm. 2013 May 6;10(5):1505-13. doi: 10.1021/mp300214k. Epub 2012 Aug 23.
3
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody.应用基因敲除小鼠模型研究 FcγR 对 MWReg30(一种单克隆抗 GPIb 抗体)药代动力学和抗血小板作用的影响。
Int J Pharm. 2013 Feb 28;444(1-2):185-92. doi: 10.1016/j.ijpharm.2013.01.001. Epub 2013 Jan 28.
4
Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.评估单克隆抗体的近红外荧光标记作为一种组织分布工具。
Drug Metab Dispos. 2014 Nov;42(11):1906-13. doi: 10.1124/dmd.114.060319. Epub 2014 Sep 10.
5
Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.IgG1 的半乳糖基化调节 FcγRIIB 介导的对鼠自身免疫性溶血性贫血的抑制作用。
J Autoimmun. 2013 Dec;47:104-10. doi: 10.1016/j.jaut.2013.09.001. Epub 2013 Sep 18.
6
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.基于生理的药代动力学(PBPK)模型,用于预测野生型和FcRn基因敲除小鼠体内IgG的组织动力学。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709. doi: 10.1007/s10928-007-9065-1. Epub 2007 Jul 18.
7
Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice.研究蛋白丢失性肠病对小鼠单克隆抗体药代动力学的影响。
AAPS J. 2017 Nov;19(6):1791-1803. doi: 10.1208/s12248-017-0135-z. Epub 2017 Aug 28.
8
Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.应用 PBPK 模型预测人结直肠癌小鼠模型中单抗在血浆和组织中的分布。
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):683-710. doi: 10.1007/s10928-012-9279-8. Epub 2012 Nov 27.
9
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.Fcγ 受体 IIb 可强烈调节树突状细胞 Fcγ 受体介导的 T 细胞活化。
J Immunol. 2012 Jul 1;189(1):92-101. doi: 10.4049/jimmunol.1103703. Epub 2012 May 30.
10
Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.Fcγ受体直接介导小鼠抗原诱导性关节炎中的软骨破坏,但不介导骨破坏:软骨损伤与骨侵蚀及关节炎症解偶联。
Arthritis Rheum. 2006 Dec;54(12):3868-77. doi: 10.1002/art.22253.

引用本文的文献

1
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.在癌症恶病质中,FcRn 和肿瘤对免疫检查点抑制剂清除率升高的贡献脱钩。
Pharmacol Res. 2024 Jan;199:107048. doi: 10.1016/j.phrs.2023.107048. Epub 2023 Dec 23.
2
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.抗体药物清除:免疫检查点抑制剂疗效的一个未充分研究的标志物。
Clin Cancer Res. 2024 Mar 1;30(5):942-958. doi: 10.1158/1078-0432.CCR-23-1683.
3
Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.
用于描述蛋白质治疗药物的吸收、分布、代谢和排泄的数学模型。
Drug Metab Dispos. 2022 Jun;50(6):867-878. doi: 10.1124/dmd.121.000460. Epub 2022 Feb 23.
4
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.治疗性抗体——天然和病理性障碍及其克服策略。
Pharmacol Ther. 2022 May;233:108022. doi: 10.1016/j.pharmthera.2021.108022. Epub 2021 Oct 20.
5
The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.利妥昔单抗的药物遗传学:对多发性硬化症中抗 CD20 治疗的潜在影响。
Neurotherapeutics. 2020 Oct;17(4):1768-1784. doi: 10.1007/s13311-020-00950-2. Epub 2020 Oct 14.
6
Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model.四价双特异性串联抗体改善淀粉样蛋白转基因小鼠模型中的脑内暴露及药效
Mol Ther Methods Clin Dev. 2020 Aug 21;19:58-77. doi: 10.1016/j.omtm.2020.08.014. eCollection 2020 Dec 11.
7
Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.儿科患者单克隆抗体的药代动力学和临床药理学。
Paediatr Drugs. 2020 Apr;22(2):199-216. doi: 10.1007/s40272-020-00382-7.
8
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.理解单克隆抗体处置过程中的个体间差异。
Antibodies (Basel). 2019 Dec 4;8(4):56. doi: 10.3390/antib8040056.
9
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.临床前模型和患者中抗体及抗体药物偶联物处置的药理学考量
Antibodies (Basel). 2019 Jan 1;8(1):3. doi: 10.3390/antib8010003.
10
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.免疫检查点抑制剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Jul;58(7):835-857. doi: 10.1007/s40262-019-00748-2.